RT @IHSMarkit: [1/6] IHS Markit's statement on the final verdict in the murder trial of former Minneapolis police officer Derek Chauvin: #…
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins2018 ISPOR Europe research on IRP

On Tuesday, we presented research at the ISPOR Europe meeting in Barcelona by Cameron Lockwood. The research looks at how liberally (or sparingly) IRP should be utilized. Fascinating research in light of the recent IRP announcements from the US
Related Posts
-
Japan’s new CEA-based price adjustments set to maintain pricing pressure on innovative drugs -
Vaccine hesitancy boosts risks from vaccine nationalism -
The risks of vaccine nationalism -
Unlocking biomarker diagnostics in Europe and the win-win for the innovative oncology sector -
Biden administration scores first legislative win for pharmaceutical pricing reform -
AMNOG ten years on: Impact on the Europe top 5 price level hierarchy -
Europe still stuck in drug shortages -
COVID19 vaccines advanced purchase agreements tracker: insights on pre-orders and prices
Explore
RELATED INDUSTRIES & TOPICS
Follow Us
Vaccine hesitancy – driven by safety concerns for adenovirus-based COVID-19 vaccines – is delaying vaccine delivery… https://t.co/V6nvvKhO6G
RT @IHSMarkit: The rollercoaster of 2020 caught #globalmarkets by surprise. So, what does our team of experts expect for 2021 and beyond?…
Biomarker testing in Europe looks potentially very promising, and provided challenges to the market access space ar… https://t.co/Kr3VTfHnj8